Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Neoplasms 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1

Interventions

Azacitidine 15Cyclophosphamide 13fludarabine phosphate 9Mycophenolic Acid 9Methotrexate 8Antilymphocyte Serum 8venetoclax 7Tacrolimus 7Cyclosporine 7Busulfan 7Peripheral Blood Stem Cell Transplantation 6Whole-Body Irradiation 5Radiotherapy 5Filgrastim 5Decitabine 5Cord Blood Stem Cell Transplantation 5Rituximab 4Arsenic Trioxide 4Sunitinib 3Sorafenib 3Methylprednisolone 3Melphalan 3Leucovorin 3Clofarabine 3ruxolitinib 2ponatinib 2idelalisib 2Sirolimus 2Moxifloxacin 2Injections 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Leukemia, Myelomonocytic, Chronic × GSK-3326595 × Clear all
NCT03614728 2023-02-06

Study to Investigate the Safety and Clinical Activity of GSK3326595 and Other Agents to Treat Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

GlaxoSmithKline

Phase 1/2 Terminated
30 enrolled 29 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Neoplasms, Leukemia, Myeloid, Acute, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡